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mated by initial low density lipoprotein (LDL) cholesterol
and the initial ratio of total cholesterol (TC) to high den-
sity lipoprotein (HDL) cholesterol.
RESULTS: Analyses will be conducted for each clinical pa-
rameter varying the parameters by appropriate amounts.
This will assess the robustness of the model and the impact
of key clinical parameters on baseline results. 
CONCLUSIONS: By separating behavioral factors from
treatment effect, the study will determine if clinical pa-
rameters play a major role in primary prevention of CHD
with cholesterol-lowering agents.
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OBJECTIVES: A study was undertaken to compare the
epidemiology and costs associated with primary preven-
tion of coronary heart disease (CHD) in males in France,
Germany, Italy, Spain, and the United Kingdom.
METHODS: Country-specific epidemiological and cost
data were collected as part of an economic evaluation of
CHD and analyzed for differences between countries. Ep-
idemiological and economic data were collected for men
in eight 5-year age groups (35–39 to 70–74 years). These
data were primarily obtained from the published litera-
ture and complemented by expert opinion.
RESULTS: Mean systolic blood pressure ranged from
125 to 132 for the 35–39 year olds and from 143.9 to
155.5 for the 70–74 year olds. Mean body mass index
ranged from 24.7 to 26.9 for the 35–39 year olds and
from 25.5 to 27.75 for the 70–74 year olds. The propor-
tion of smokers ranged from 0.38 to 0.56 for the 35–39
year olds and from 0.2 to 0.29 for the 70–74 year olds.
With adjustment by the respective health purchasing
power parities, direct costs of CHD ranged from £11,515
to £20,431 for acute myocardial infarction, £8,484 to
£17,898 for complicated angina, £606 to £10,227 for un-
complicated angina, and £305 to £9,734 for sudden and
nonsudden death. 
CONCLUSIONS: The epidemiological data showed simi-
lar trends within the five countries with some observed dif-
ferences for certain variables and/or age groups. Resource
utilization data differed significantly between countries—a
not surprising finding considering the profound differences
in healthcare systems and treatment patterns across Eu-
rope. In addition, differences in currency values and unit
costs make direct comparison of costs difficult.
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OBJECTIVE: We conducted a health economic and out-
comes study of post-menopausal women in Belgium to
quantify the benefits and risks associated with HRT. Us-
ing data provided by l’Université Catholique de Louvain,
the analysis was designed to predict the long-term clinical
and economic effects related to the conjugated estrogens/
medroxyprogesterone HRT (E/M HRT) regimen.
METHODS: Hypothetical cohorts of uterine-intact post-
menopausal women who were fully compliant with E/M
HRT were compared with similar cohorts of post-meno-
pausal women who did not use any form of HRT.
Markov cohort simulation analysis, guided by a Delphi
panel of local clinical and health economic experts, was
employed to model the short- and long-term implica-
tions of compliance with E/M HRT. Eight distinct health
states were considered in the analysis: healthy, osteo-
porosis, coronary heart disease, cerebrovascular disease,
Alzheimer’s Disease, breast cancer, colorectal cancer, and
death.
RESULTS: Results of this analysis suggest that patients
using E/M HRT therapy are expected to experience im-
proved health outcomes and an increased life expectancy
of more than 5 months per patient when compared those
not on HRT. These results are achieved with a modest
increase in cost of 8,415 BF, or 18,300 BF per life-year
gained.
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OBJECTIVE: To address willingness to pay (WTP) of pa-
tients with painful-irritable bladder syndrome (PIBS) us-
ing a regression model.
METHODS: A sample of 60 patients with PIBS from Se-
attle and Philadelphia were interviewed. The survey ques-
tionnaire contained a WTP question with 11 bids ranging
from $1 to $200. Two versions of the questionnaire were
administered, one for “improvement” of the condition
and one for “cure.” Respondents recorded whether they
would accept or reject each bid at the stated dollar value.
